中轴型脊柱关节炎生物制剂随机对照试验中安慰剂与治疗效应随时间变化的系统评价与荟萃分析
结果显示ASAS20和ASAS40的治疗效应随时间下降,主要由安慰剂反应增加及ASAS40治疗反应下降驱动;而基于ASDAS的终点治疗效应保持稳定,提示ASDAS终点对安慰剂效应和时间趋势更稳健。
核心结论
- 在中轴型脊柱关节炎随机对照试验中,ASAS20/40治疗效应随时间下降,与报告有效性减弱一致,而ASDAS-based终点保持稳定,表明对安慰剂效应和时间趋势更稳健。
关键数值与推荐
- 主要结局为每个试验主要终点时ASAS20/40、ASDAS临床重要改善和ASDAS非活动疾病的安慰剂反应时间趋势。
- 采用随机效应荟萃回归估计治疗效应(比值比)和臂别反应率的年变化,调整年龄、性别、放射学状态、地区、给药途径、基线BASDAI评分、基线C反应蛋白和病程。
临床怎么用
- ASDAS-based终点在评估中轴型脊柱关节炎生物制剂疗效时可能比ASAS20/40更稳健,受安慰剂效应和时间趋势影响较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate temporal trends in treatment efficacy and placebo responses in randomized controlled trials in axial spondyloarthritis (axSpA). METHODS: We conducted a systematic review of RCTs in MEDLINE up to July 2024 (PROSPERO: CRD42024563776). Eligible trials compared tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, infliximab, golimumab) or interleukin-17 inhibitors (bimekizumab, ixekizumab, secukinumab) versus placebo in axSpA. Two reviewers independently selected studies and extracted data. Primary outcomes were temporal trends in placebo response for Assessment of SpondyloArthritis International Society 20% and 40% response criteria (ASAS20/40), axSpA Disease Activity Score (ASDAS) Clinically Important Improvement, and ASDAS Inactive Disease (ASDAS-ID) at each trial's primary endpoint. Random-effects meta-regressions estimated annual changes in treatment effects (odds ratios) and in arm-specific response rates, adjusted for age, sex, radiographic status, region, route of administration, baseline Bath Ankylosing Spondylitis Disease Activity Index score, baseline C-reactive protein, and disease duration. RESULTS: Thirty-one RCTs (n = 6437) were included. Treatment effect declined over time for ASAS20 (-5% per year, P < .001) and ASAS40 (-3.7%, P = .04), driven by increased placebo response (ASAS20: +1% per year, P < .0001) and a decline in treatment response for ASAS40. In contrast, ASDAS-based treatment effects were stable, despite a small increase in placebo ASDAS-ID (+0.19% per year, P < .05). CONCLUSIONS: ASAS20/40 treatment effects have declined over time in axSpA trials, consistent with a fading of reported effectiveness, whereas ASDAS-based endpoints remain stable, indicating greater robustness to placebo effects and temporal trends.
引用
- Perrot L, Molto A, Paris C, et al. Evaluation of the placebo and treatment effect overtime in randomised clinical trials evaluating the efficacy of biologics in axial spondyloarthritis: systematic review and meta-analysis. Ann Rheum Dis. 2025. PMID: 41448991. doi:10.1016/j.ard.2025.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。